Earlier this week,
Accelrys, Inc.
(
ACCL
) declared its purchase of Web-based Hit Explorer Operating System
(HEOS) from drug manufacturing company, SCYNEXIS, Inc. This
completed the contract entered into by both parties in 2011 for the
marketing of HEOS using Accelrys' Cheminformatics Suite of software
applications.
The HEOS Software-as-a-Service (SaaS) platform induces better
management and brings forth advanced research tools which provide
celerity to drug development and discovery. These include
biological assay results, advanced analytical tools and historical
data access. Not only do these features come in a flexible and
secure solution package, but are also immensely user-friendly and
affordable.
Accelrys shall be able to ameliorate its research development
procedures and also address a larger scientific forum using the
HEOS package. Hence, market share proliferation and goodwill
enhancement seem to be on the cards for the company through this
integration.
The company has maintained a proactive stance with regard to
escalating product standards and opting for technological
advancements. In its first quarter financial results declared on
May 3, 2012, the company reported a 64% annual hike in expenses
accrued for product development to reach $0.38 million in the
quarter. It is praiseworthy that Accelrys is wholeheartedly devoted
to enhancing and developing its product portfolio even in times of
clouded macro conditions.
However, there are companies which threaten Accelrys' formidable
industry position at all times. These include big players such as
MSCI Inc.
(
MSCI
),
RealPage, Inc.
(
RP
) and
Guidewire Software, Inc
. (
GWRE
).
The company currently retains a Zacks #2 Rank, which translates
into a short-term 'Buy' rating. However, we presently maintain our
'Neutral' recommendation on the stock.
ACCELRYS INC (ACCL): Free Stock Analysis Report
GUIDEWIRE SFTWR (GWRE): Free Stock Analysis
Report
MSCI INC-A (MSCI): Free Stock Analysis Report
REALPAGE INC (RP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment
Research